Sarcoma Clinical Trial
Official title:
A Phase II Study to Evaluate the Preliminary Efficacy Assessment of Caphosol in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide or Cisplatin
The goal of this clinical research study is to find out if Caphosol® (calcium phosphate)
mouthwash is more effective than a baking soda solution at preventing and treating
mucositis, in patients with sarcoma who are to be treated with chemotherapy. The safety of
this drug will also be studied. Researchers also want to learn about the way calcium
phosphate may affect mucous membranes.
The goal of this clinical research study is to see if Caphosol® (calcium phosphate)
mouthwash is better than baking soda solution in patients with sarcoma who are to be treated
with chemotherapy . Caphosol will also be studied to see if it lessens the incidence and
severity of oral mucositis (painful sores in the mouth).
Chemotherapy and radiation therapy can hurt normal cells in the gastrointestinal tract
(which includes the mouth and intestines). When this happens, it can cause mucositis
(inflammation of the lining of the mouth, throat, and intestines). Researchers want to
compare the effects of calcium phosphate and baking soda on patients who are at risk for
mucositis.
The Study Drugs:
Caphosol (calcium phosphate) is a saliva-like liquid that is designed to replace the
chemical and pH (acid) balance in the mouth. It is used as a mouth rinse to moisten,
lubricate, and clean the mouth, including the lining of the mouth, tongue, and throat. It is
also used to loosen thick mucous and help prevent the mucous membranes from sticking
together.
Baking soda is used as the standard of care for preventing and treating mucositis.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the flip of a coin) to receive either calcium phosphate mouth rinse or the baking
soda mouth rinse during the study. There is an equal chance of being assigned to either
group.
You will use the mouth rinse 5 times every day. The study staff will explain how to mix and
rinse with it.
Calcium phosphate should be stored at room temperature and should not be refrigerated. If
you are on a low sodium diet, you should check with your doctor before using calcium
phosphate.
Baseline Tests:
The following tests and procedures will be performed before you receive your first dose of
chemotherapy:
- Blood (about 3 teaspoons) will be drawn for routine tests.
- The mucous membranes in your mouth will be checked.
- You will be asked to complete a questionnaire (about 15 minutes) on how you feel.
- You will be given a diary before you start each cycle to record if you have any mouth
pain.
Study Tests:
You will need to come to MD Anderson on around Days 10, 12, and 14 (depending on the status
of the mucositis) of each chemotherapy cycle. During these clinic visits, the following
tests and procedures may be performed:
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 3 teaspoons) will be drawn for routine tests.
- The mucous membranes in your mouth will be checked. Also, you may have your mouth and
throat photographed.
- You will be asked to complete the questionnaire on how you feel.
- When possible, the optical imaging procedures will also be performed on these days.
Length of Study and Reasons for Leaving the Study Early:
You will take part in this study for up to 18 weeks (4 to 5 months). You will be taken off
study if you experience intolerable side effects.
End of Study Visit:
You will also have an end of study visit after you complete 6 cycles of study drug, if you
are taken off study for any reason, or if you choose to leave the study. During this visit,
the following tests and procedures will be performed:
- You will have a physical exam, including measurement of your vital signs and weight.
- Blood (about 3 teaspoons) will be drawn for routine tests.
- The mucous membranes in your mouth will be checked.
- You will be asked to complete the questionnaire on how you feel.
- You will receive a phone call from the nurse after you last dose of study drug to
follow up on any side effects.
This is an investigational study. Caphosol (calcium phosphate) is FDA approved and
commercially available for use in preventing and treating mucositis, and for relief of dry
mouth during high dose chemotherapy or radiation treatment.
Up to 30 patients will take part in this study. All will be enrolled at M. D Anderson.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Recruiting |
NCT04457258 -
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
|
Early Phase 1 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT04535713 -
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
|
Phase 2 | |
Completed |
NCT03521531 -
Burden and Medical Care of Sarcoma in Germany
|
||
Completed |
NCT02496520 -
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
|
Phase 1/Phase 2 | |
Terminated |
NCT02054104 -
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
|
Phase 1/Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT04052334 -
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT01593748 -
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Completed |
NCT01879085 -
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT01209598 -
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
|
Phase 2 | |
Completed |
NCT04553471 -
Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
|
N/A | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 |